T2 Biosystems Completes $40M Series E

T2 Biosystems, a developer of medical diagnostic products, has closed a $40 million Series E round of financing led by new investor Goldman Sachs, with participation from existing investors Flagship Ventures, Polaris Partners, Aisling Capital, Flybridge Capital Partners, Physic Ventures, Arcus Ventures, Partners Healthcare, Camros Capital and WS Investments. The Lexington, MA-based company will use the new capital to support clinical programs and the commercialization of T2Candida, T2's flagship molecular diagnostic test panel for the early diagnosis and treatment of sepsis caused by the fungal pathogen Candida.

Related content